Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis

被引:0
|
作者
Zjukovskaja, Christina [1 ]
Larsson, Anders [1 ]
Cherif, Honar [1 ]
Kultima, Kim [1 ]
Burman, Joachim [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden
基金
瑞典研究理事会;
关键词
Multiple sclerosis; Autologous hematopoietic stem cell; transplantation; Demyelination; Neurofilament light chain; Myelin basic protein; Glial fibrillary acidic protein;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Autologous hematopoietic stem cell transplantation (aHSCT) has seen increased use for relapsing -remitting multiple sclerosis (RRMS) in recent years. It is considered one of the most effective treatments for RRMS and has been associated with improvement in disability and prolonged remission. This suggests that the tissue-injuring disease process may have been altered by aHSCT. To assess whether this hypothesis is correct, we performed a study of three commonly used cerebrospinal fluid biomarkers of tissue damage.Methods: In this single center study, 63 patients treated with aHSCT at Uppsala University Hospital between January 1st 2012 and January 31st 2019 were screened for participation. A control group consisting of volun-teers without neurologic disease were included as a reference. Cerebrospinal fluid concentrations of neurofila-ment light (NFL), myelin basic protein (MBP) and glial acidic fibrillary protein (GFAp) were determined using ELISA and a multiplex proteomics platform from Meso Scale Discovery.Results: Forty-three patients with a mean age of 31 and a median follow-up time of 3.9 years were included. Their median baseline expanded disability status scale (EDSS) score was 3.5 and the annualized relapse rate in the year preceding aHSCT was 1.6. At baseline the proportion of patients with values above the upper limit of normal was 67% for NFL, 63% for MBP and 16% for GFAp. At 5-year follow-up, the proportion of patients with values above the upper limit of normal was 12% for NFL, 12% for MBP and 25% for GFAp. The mean concentration of NFL decreased from 920 pg/mL at baseline to 270 pg/mL at 5-year follow-up (p < 0.001); MBP decreased from 1500 to 680 pg/mL (p < 0.001); whereas the mean concentration of GFAp was unchanged.Conclusion: In a majority of patients, biomarkers of demyelination and axonal damage reached normal values within five years from treatment with aHSCT.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Autologous hematopoietic stem cell transplantation in multiple sclerosis: intermediate results
    Malko, V.
    Bisaga, G.
    Topuzova, M.
    Alekseeva, Y.
    Osipov, Y.
    Motorin, D.
    Krinizina, T.
    Alekseeva, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 641 - 641
  • [22] Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis
    Pandit, Awadh Kishor
    Prasad, Kameshwar
    Seth, Tulika
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2015, 18 (04) : 459 - 463
  • [23] Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol
    Puyade, Mathieu
    Brunet, Francis
    Carolina, Rush
    Fergusson, Nathan
    Makedonov, Ilia
    Freedman, Mark S.
    Atkins, Harold
    CURRENT PROTOCOLS, 2022, 2 (05):
  • [24] AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: THE SWEDISH EXPERIENCE
    Hagglund, H. Gustaf
    Fagius, J.
    Iacobaeus, E.
    Svenningsson, A.
    Lycke, J.
    Gunnarsson, M.
    Nilsson, P.
    Vrethem, M.
    Fredrikson, S.
    Martin, C.
    Sandstedt, A.
    Uggla, B.
    Lenhoff, S.
    Johansson, J. -E.
    Isaksson, C.
    Carlson, K.
    Burman, J.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S41 - S42
  • [25] Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis
    Saiz, A.
    Blanco, Y.
    Berenguer, J.
    Gomez-Choco, M.
    Carreras, E.
    Arbizu, T.
    Graus, F.
    NEUROLOGIA, 2008, 23 (07): : 405 - 407
  • [26] Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series
    Mariottini, Alice
    Boncompagni, Riccardo
    Cozzi, Diletta
    Simonetti, Edoardo
    Repice, Anna Maria
    Damato, Valentina
    Giordano, Mirella
    Miele, Vittorio
    Nozzoli, Chiara
    Massacesi, Luca
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
    Muraro, Paolo A.
    Pasquini, Marcelo
    Atkins, Harold L.
    Bowen, James D.
    Farge, Dominique
    Fassas, Athanasios
    Freedman, Mark S.
    Georges, George E.
    Gualandi, Francesca
    Hamerschlak, Nelson
    Havrdova, Eva
    Kimiskidis, Vassilios K.
    Kozak, Tomas
    Mancardi, Giovanni L.
    Massacesi, Luca
    Moraes, Daniela A.
    Nash, Richard A.
    Pavletic, Steven
    Ouyang, Jian
    Rovira, Montserrat
    Saiz, Albert
    Simoes, Belinda
    Trneny, Marek
    Zhu, Lin
    Badoglio, Manuela
    Zhong, Xiaobo
    Sormani, Maria Pia
    Saccardi, Riccardo
    JAMA NEUROLOGY, 2017, 74 (04) : 459 - 469
  • [28] THE QUALITY OF LIFE OF PERSONS WITH MULTIPLE SCLEROSIS IMPROVES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Lira-Lara, Olivia
    Gallardo-Perez, Moises Manuel
    Melgar-de-la-Paz, Miranda
    Negrete-Rodriguez, Paola
    Hamilton-Aviles, Luis Enrique
    Ocana-Ramm, Guillermo
    Robles-Nasta, Max
    Sanchez-Bonilla, Daniela
    Olivares-Gazca, Juan Carlos
    Ruiz-Delgado, Guillermo Jose
    Ruiz-Arguelles, Guillermo Jose
    BONE MARROW TRANSPLANTATION, 2024, 59 : 197 - 198
  • [29] Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
    Moraes, Daniela A.
    Oliveira, Maria Carolina
    JOURNAL OF BLOOD MEDICINE, 2021, 12 : 951 - 964
  • [30] Autologous hematopoietic cell transplantation in multiple sclerosis
    Bell, Simon M.
    Sharrack, Basil
    Snowden, John A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (01) : 77 - 86